Published Online
on
May 28, 2002
Circulation. 2002
Published online before print May 28, 2002,
doi: 10.1161/01.CIR.0000022405.68464.CA
A more recent version of this article appeared on July 2, 2002
© American Heart Association, Inc.
Clinical Investigation and Reports |
Cardiomyocytes of Noncardiac Origin in Myocardial Biopsies of Human Transplanted Hearts
Patrick Müller, MD;
Peter Pfeiffer, MS;
Jörg Koglin, MD;
Hans-Joachim Schäfers, MD;
Ute Seeland, MD;
Ingrid Janzen, MD;
Steffi Urbschat, PhD
Michael Böhm, MD
From the Departments of Innere Medizin III (P.M., P.P., U.S., I.J., M.B.), Thorax- und Herz-Gefäßchirurgie (H.-J.S.), and Humangenetik (S.U.), Universität des Saarlandes, Homburg/Saar, Germany, and the Medizinische Klinik I (J.K.), Universitätsklinikum Großhadern, Ludwig-Maximilians-Universität, München, Germany.
Correspondence to Michael Böhm, MD, Innere Medizin III, Universitätskliniken des Saarlandes, Kirrberger Str, 66421 Homburg, Germany. E-mail boehm{at}med-in.uni-saarland.de
 |
Abstract
|
|---|
Background— Cell replacement therapy with stem cells able
to differentiate into cardiomyocytes has been discussed as a
method for remodeling damaged myocardium. A physiological or
pathophysiological situation in which this phenomenon might
be relevant is not known. We studied the origin of cardiomyocytes
in myocardial biopsies of male patients that had undergone sex-mismatched
cardiac transplantation to determine whether cells containing
a Y chromosome (and therefore being of recipient origin) are
able to differentiate into cardiomyocytes.
Methods and Results— Myocardial biopsies (n=21) were obtained from the right ventricles of male patients (n=13) who had undergone sex-mismatched heart transplantation. Tissue from 1 nontransplanted male and myocardial biopsies from sex-matched heart–transplanted patients served as controls. Cells from donor and recipient origins were identified by fluorescence in situ hybridization with the use of specific probes for X and Y chromosomes on paraffin sections of the biopsies. Cell types were identified by using immunostaining procedures on the same tissue sections. Cardiomyocytes of recipient origin were detected in 8 of 13 male recipients of female hearts. They were connected by gap junctions with adjacent myocytes. Of the cardiomyocyte nuclei, 0.16±0.04% (mean±SEM, median 0.09%) contained the Y-chromosomal marker. There was no detectable correlation with the extent or number of rejection episodes, time of transplantation, or medical treatment regimen.
Conclusions— These results show that regeneration by cells of noncardiac origin (differentiated into cardiomyocytes and physiologically linked to neighboring myocytes) can be detected even in small myocardial biopsies. This may lead to new diagnostic and therapeutic strategies in the treatment of myocardial infarction, inflammatory heart disease, and/or heart failure.
Key Words: transplantation • sex • heart diseases • genes • cells
|
Introduction
|
|---|
For the last few decades, it has been widely accepted that the
cardiac muscle is a terminally differentiated organ that is
not capable of regeneration and that cardiac myocytes withdraw
from the cell cycle after birth. Recently, evidence of myocyte
proliferation in end-stage cardiac failure
1 and in human hearts
after myocardial infarction
2 has been provided. Because of reports
of bone marrow–derived cells differentiating into cardiomyocytes
in rodents,
3–6 we wondered whether this process occurs
in human myocardium, whether it could potentially contribute
to myocardial regeneration in humans, and whether such a phenomenon
could also be detected with the use of routine myocardial biopsy
specimens. An ideal constellation for the study of the engraftment
of cells can be found in male recipients of female donor hearts,
because in these patients, cardiomyocytes of recipient (male)
origin can be identified by the Y chromosome. Therefore, we
examined myocardial biopsies of sex-mismatched transplanted
patients by in situ hybridization for Y and partially X chromosomes
to detect cardiomyocytes engrafted from cells of recipient origin.
We also sought to determine whether the newly formed cells were
connected by gap junctions with adjacent cardiomyocytes.
|
Methods
|
|---|
Patients
We studied 21 biopsies from 13 male heart transplant recipients
who received organs from female donors. Data about underlying
heart disease as a cause for transplantation, time of biopsy,
patient age, rejection grade according to the International
Society of Heart and Lung Transplantation, and medications are
shown in the
Table.
From all patients, right ventricular myocardial biopsies were taken according to the posttransplantation evaluation program. All heart specimens were fixed in 4% PBS-buffered formalin and were paraffin-embedded according to standard procedures. As positive controls, right ventricular sections from the explanted heart of a male patient with dilated cardiomyopathy and from the heart biopsy of a male sex-matched transplanted patient were used. Negative controls included biopsies of 2 sex-matched transplanted female patients.
Immunofluorescence Analysis
Immunofluorescence study was performed on 6-µm-thick sections by applying monoclonal antibodies against 
-sarcomeric actin (clone 5c5, Sigma Chemical Co) and myoglobin (Sigma) to detect cardiomyocytes. Serial sections were also counterstained for endothelial cells (von Willebrand factor, clone F8/68, DAKO), smooth muscle cells (anti–-smooth muscle actin, clone 1A4, Sigma), leukocyte common antigen (CD45RB, DAKO), and macrophages (CD68, clone KP1, DAKO). Immunostaining for connexin43 (Sigma) was used to detect intercellular connections and electrical coupling between the cardiomyocytes. Fluorescein isothiocyanate–conjugated anti-mouse IgM, anti-mouse IgG, and anti-rabbit IgG were used as secondary antibodies (1:25, Dianova). The slices were microwave-treated at 560 W for 5 minutes and then incubated for 1 hour at 37°C with the first antibody, followed by the appropriate secondary antibody for 45 minutes.
Because digestion with proteinase K (see below) obliterated antigenic sites for -sarcomeric actin antibody binding, these sections were counterstained immediately after cardiomyocyte immunostaining with Vectorshield Mounting Medium with DAPI (Vector Laboratories) for detecting nuclei and then systematically and thoroughly photographed at a magnification of x400. The photographs were later compared with photographs taken after fluorescence in situ hybridization (FISH) to identify cardiomyocyte nuclei.
Fluorescence In Situ Hybridization
After immunostaining, FISH was performed as described elsewhere,7 with only minor modifications. Pretreated slices were digested with proteinase K (2 µg/mL, Sigma) for 5 minutes.
The presence of chromosome X was detected with the use of the biotinylated -satellite DNA probe DXZ1 (Q-Biogene), and the presence of chromosome Y was detected by DNA probe Y3.4 (American Type Culture Collection, vector pBR322, digoxigenin-labeled with the Nick Translation System [GIBCO-BRL Life Technologies]).
The biotin-labeled probe DXZ1 was detected by fluorescein streptavidin (Vector Laboratories) and amplified with the use of a biotinylated anti-streptavidin antibody (Vector Laboratories) and, again, fluorescein streptavidin. The digoxigenin-labeled probe Y3.4 was detected by anti–digoxigenin-Cy3 (Dianova).
Tissue Analysis
Sections stained for -sarcomeric actin were examined at a magnification of x400 with a Nikon E 600 microscope (Nikon Europe) equipped with filters suitable for 4',6-diamidino-2-phenylindole and fluorescein isothiocyanate. Photographs were taken with a Nikon DXM1200 digital camera (Nikon Europe). These images were later correlated with the corresponding micrographs obtained after FISH (see below) to identify hybridization signals in cardiomyocyte nuclei. FISH signals and immunostaining other than with -sarcomeric actin were evaluated field by field at a magnification of x1000 with an Olympus-BX-70 epifluorescence microscope with suitable filters for 4',6-diamidino-2-phenylindole, fluorescein isothiocyanate, and Cy3. Evaluation was performed according to the strict criteria of Hopman et al.8 Two independent microscopic examiners (P.M. and P.P.) were blinded to the donor/recipient status. To exclude the possibility of detecting overlapping nuclei of nonmyocytes, only single located nuclei, totally surrounded by cardiomyocyte cytoplasm, were counted (see the Table).
In the positive controls, at least 400 nuclei were counted to examine hybridization efficiency of the Y probe. In the biopsies of male recipients of a female heart and in the negative controls, all nuclei identified as being of cardiomyocyte origin were counted. Photographs of hybridization signals were taken with the use of a Hamamatsu C4742-95 digital camera (Hamamatsu Photonics K.K.) and specialized software (ISIS 4, Metasystems).
|
Results
|
|---|
The biopsies of 2 sex-matched transplanted female patients,
serving as negative controls, showed no Y chromosome at all
in a total of 2053 of 3801 examined cardiomyocyte nuclei. Positive
controls yielded a high percentage of cardiomyocytes with the
Y chromosome: 66.47±2.78% (mean±SEM) of the cardiomyocyte
nuclei in the nontransplanted male patient and 55% of the cardiomyocyte
nuclei in the sex-matched transplanted male patient showed an
Y chromosome.
In serial sections of cardiac muscles from right ventricular biopsies of female donor hearts implanted into male patients, single cardiomyocytes contained Y chromosomes (and, thus, were of male origin) in 8 of 13 sex-mismatched transplanted patients (Table). Cardiomyocyte nuclei containing a Y chromosome (see Figure 1) and, therefore, being of recipient (male) origin were located as single cells and were not found to occur in clusters. Of the 31 787 cardiomyocytes studied, 0.16±0.04% (mean±SEM, median 0.09%) were of recipient origin (for details, see the Table). The numbers of examined cardiomyocyte nuclei ranged from 73 to 2387 per biopsy. Biopsy samples containing the Y chromosome tended to be bigger and, therefore, to contain more nuclei per section (range 598 to 2387 nuclei versus 73 to 664 nuclei in sections of negative-biopsy specimens). In 6 patients, we were able to examine biopsies obtained at 2 different time points (Table). A significant increase of recipient-derived cells over time was not detected. In 5 of these patients, both biopsies contained cardiomyocyte nuclei with a Y chromosome. In 1 case, the first biopsy was negative, and the second was positive. For 1 patient, we sampled 3 small biopsies from different time points, which were all negative.
View larger version (90K):
[in this window]
[in a new window]
|
Figure 1. Results of immunostaining and in situ hybridization for Y and X chromosomes. In panels A through D, blue areas show DAPI staining of nuclei. In panels B through D, red dots indicate Y chromosomes, and green dots indicate X chromosomes in nuclei. Panel A shows immunostaining of myocardial biopsy by -sarcomeric actin (green area). Cardiomyocyte marked by arrow is also shown after in situ hybridization in panel B. Green staining surrounding nucleus in panel B is due to autofluorescence. In panels C and D, green areas represent immunostaining for myoglobin; arrows indicate male cardiomyocytes. Asterisk in panel D indicates nucleus belonging to male nonmyocyte cell. Bars=10 µm.
|
|
The newly formed cardiomyocytes formed intercellular connections with the surrounding myocardium; these were shown by immunostaining with a connexin43 antibody (see Figure 2).
View larger version (84K):
[in this window]
[in a new window]
|
Figure 2. Immunostaining and in situ hybridization for Y chromosome. In panels A through E, blue areas show DAPI staining of nuclei; red dots indicate Y chromosomes. In panels A through D, large dark green areas surrounding nuclei are due to autofluorescence. In panels A and B, bright green areas indicated by asterisks represent immunostaining for connexin43. Arrows indicate male cardiomyocytes. Panels C through E show immunostaining (bright green signals; male cells are marked by arrows) for CD68 (panel C), CD45 (panel D), and von Willebrand factor (panel E). Bars=10 µm.
|
|
Nuclei containing a Y chromosome were also found in endothelial (see Figure 2) and smooth muscle cells (but at a higher frequency than in cardiomyocytes) and even in biopsies not showing fluorescence signals for the Y chromosome in cardiomyocytes. Because there were only small numbers of endothelial and smooth muscle cells in the myocardial biopsies and because endothelial nuclei often overlapped, quantification was not reliable and, therefore, not performed. Macrophages and leukocytes were in the majority for cells of recipient origin (see Figure 2).
|
Discussion
|
|---|
Recently, there has been increasing evidence that adult cells
have far greater plasticity than previously thought, with bone
marrow–derived cells turning into skeletal muscle,
9 liver,
10 brain,
11 endothelium,
12,13 and even cardiac muscle.
3–5,14 Although the findings of cardiomyocytes formed from bone marrow
in rodents have been suggestive, it has been impossible to extrapolate
these findings to human physiology without studying human tissues
directly. Using the therapeutic "experiment" of sex-mismatched
heart transplantation, we conclude that the human adult heart
has the power to regenerate cardiomyocytes by recruiting cells
of noncardiac origin.
The newly formed cardiomyocytes were intercellularly connected and, therefore, probably electrically coupled with other cardiomyocytes, as shown by immunostaining for connexin43, which is an integral membrane protein constituent of gap junctions.15
Numbers of newly formed cardiomyocytes attained a mean±SEM of 0.16±0.04% with a median of 0.09%, but the real percentage might have been underestimated. Because of hybridization efficiency and partial sampling of nuclei in the 6-µm thin tissue sections, the Y-chromosome probe in positive controls was detected in only 66.47±2.78% of the cardiomyocyte nuclei in the patient with dilated cardiomyopathy and in 55% of the cardiomyocyte nuclei in the sex-matched transplanted male patient. Therefore, one might speculate that replacement would be more pronounced when cardiac injury is more severe. A recently published study by Quaini et al,16 who examined sex-mismatched transplanted hearts after the subjects had died, has shown higher numbers of cardiac chimerism, although our hybridization efficiency was comparable. But in another postmortem study,17 prevalence of newly built cardiomyocytes was also very low (0.04%). One reason for the difference between the study of Quaini et al and our findings may be that we used very strict criteria8 in our fluorescence microscopic setting to define nuclei as being of cardiomyocyte origin: We counted nuclei only if they were surrounded totally by myocytic cytoplasm and if there was no other nucleus visible in the same cell. In addition, none of our patients had episodes of severe rejection, whereas most patients in the study of Quaini et al had died because of graft failure or other inflammatory causes, which may have contributed to their higher numbers. So our cases may more likely represent the real regeneration status in the living. But taking into account the fact that Laflamme et al17 also found very low numbers in their autoptic cases, we found that to be a rather unsatisfactory explanation. In the end, the difference may also be due to the fact that the interval between transplantation and death was much shorter in the study of Quaini et al than the interval between transplantation and biopsy in our patient group and in the patient group of Laflamme et al. So one mechanism could be that after transplantation, a rather high number of new cells showing signs of cardiomyocyte differentiation are built, but they die rather quickly. On the other hand, it is imaginable that the patients of Quaini et al had rather high rates of inflammatory cells in their newly transplanted hearts, so that many of the Y-positive nuclei belonged to overlapping nuclei of leukocytic cells than to real cardiomyocytes.
Biopsy samples showing no Y chromosome tended to be smaller and to contain fewer nuclei. Therefore, one cannot exclude the possibility that an impact of a low number of nuclei might also be responsible for an underestimation of regenerated cells in human transplanted hearts. However, these limitations would lead to an underestimation but not to an overestimation of regenerated myocardial cells. While interpreting the presented data, one must also keep in mind that samples were from transplanted patients who had all suffered more or less from rejection episodes. This may have represented a stimulating factor for the recruitment of stem cells. So the numbers of regenerated cardiomyocytes may be larger in transplanted patients than in people not suffering from transplant rejection (such as healthy persons). On the other hand, the number of regenerated myocytes may be comparable or even higher in patients suffering from myocardial infarction or dilated cardiomyopathy, in which mitotic index and expression of Ki-67 (a nuclear protein associated with cell proliferation) as a sign of cell division have been shown to be increased.1,2 In line with a significant regeneration in diseased hearts is the finding that the number of cardiomyocytes increases rather than decreases with hypertrophy in congestive heart disease.18
Other authors detected proliferating myocytes expressing Ki-67 after myocardial infarction in mice and reported that these mitotic active cells were derived either from resident cardiomyocytes or from circulating stem cells.4 Our results indicate the existence of noncardiac cells that are able to differentiate into cardiomyocytes, because the detected Y chromosome–containing cells could be derived only from the host organism and not from resident cells of the donor heart. This finding is supported by another study,19 in which mice after myocardial infarction were treated with stem cell factor and granulocyte colony–stimulating factor. These animals showed the production of functional healthy myocardium after receiving this form of therapy. A similar approach, raising numbers of immigrating and engrafting cells to build significant new cardiac muscle mass, could be undertaken in humans. It would be an interesting alternative or at least an addition to the transplantation of myoblasts, fetal cardiomyocytes, or stem cells into damaged hearts as proposed by others.6,20–22 The present study provides evidence for the applicability of this principle.
In summary, these results challenge the dogma that the heart is not able to regenerate. Recruitment of noncardiac cells may be a component of the growth reserve of the human heart. Although the percentage of regenerated cardiomyocytes is rather low, the mechanism could be used to replace damaged myocardium by raising the numbers and by promoting the migration of the respective precursor cells into damaged myocardium. Such a therapeutic approach could be an interesting alternative to the transplantation of myoblasts, fetal cardiomyocytes, or stem cells. But because of the low numbers of newly generated cells in transplanted patients, further studies are necessary to determine whether it is possible to regenerate enough cardiomyocytes to significantly enhance the pump function of a damaged heart. Because the newly built cardiomyocytes can be detected in diagnostic biopsies, the amount of cellular reparation could be a marker of precedent damages imposed on the heart, therefore acting like a cardiac memory.
|
Acknowledgments
|
|---|
We are indebted to Wolfgang Feiden, MD, from the local Institute
of Neuropathology, who provided paraffin sections of myocardial
biopsies and histological diagnosis concerning rejection episodes.
Julia Andres supported us with excellent technical assistance.
Received April 2, 2002;
accepted May 1, 2002.
|
References
|
|---|
1.
Kajstura J, Leri A, Finato N, et al. Myocyte proliferation in end-stage cardiac failure in humans.
Proc Natl Acad Sci U S A. 1998;95:8801–8805.
2.
Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiomyocytes divide after myocardial infarction. N Engl J Med. 2001; 344: 1750–1757.[Abstract/Full Text]
3.
Bittner RE, Schöfer C, Weipoltshammer K, et al. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat Embryol. 1999; 199: 391–396.[Medline]
4.
Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701–705.[Medline]
5.
Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001; 107: 1395–1402.[Abstract/Full Text]
6.
Tomita S, Li R-K, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 1999; 100 (suppl II): II-247–II-256.[Medline]
7.
Lutz S, Welter C, Zang KD, et al. A two-colour technique for chromosome in situ hybridization in tissue sections. J Pathol. 1992; 167: 279–282.[Medline]
8.
Hopman AHN, Ramaekers FCS, Raap AK, et al. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry. 1989; 89: 307–316.
9.
Ferrari G, Cusella-De Angelis G, Coletta M, et al. Muscle regeneration by bone-marrow-derived myogenic progenitors. Science. 1998;279:1528–1530.
10.
Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology. 2000; 32: 11–16.[Medline]
11.
Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A. 1997;94:4080–4085.
12.
Gunsilius E, Duba H-C, Petzer AL, et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet. 2000; 355: 1688–1691.[Medline]
13.
Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998; 92: 362–367.[Abstract/Full Text]
14.
Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999; 103: 697–705.[Abstract/Full Text]
15.
Musil LS, Le A-CN, VanSlyke JK, et al. Regulation of connexin degradation as a mechanism to increase gap junction assembly and function. J Biol Chem. 2000;275:25207–25215.
16.
Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med. 2002; 346: 5–15.[Abstract/Full Text]
17.
Laflamme MA, Myerson D, Saffitz JE, et al. Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res. 2002; 90: 634–640.[Abstract/Full Text]
18.
Grajek S, Lesiak M, Pyda M, et al. Hypertrophy or hyperplasia in cardiac muscle: post-mortem morphometric study. Eur Heart J. 1993; 14: 1–3.
19.
Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98:10344–10349.
20.
Etzion S, Battler A, Barbash IM, et al. Influence of embryonic cardiomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction. J Mol Cell Cardiol. 2001; 33: 1321–1330.[Medline]
21.
Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation. 2000; 103: 1920–1927.[Abstract/Full Text]
22.
Dorfman J, Duong M, Zibaitis M, et al. Myocardial tissue engineering with autologous myoblast implantation. J Thorac Cardiovasc Surg. 1998; 116: 744–751.[Abstract/Full Text]
This article has been cited by other articles:
|
|
|
|
 
S. G. Macambira, J. F. Vasconcelos, C. R. S. Costa, W. Klein, R. S. Lima, P. Guimaraes, D. T. A. Vidal, L. C. Mendez, R. Ribeiro-dos-Santos, and M. B. P. Soares
Granulocyte colony-stimulating factor treatment in chronic Chagas disease: preservation and improvement of cardiac structure and function
FASEB J,
November 1, 2009;
23(11):
3843 - 3850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Boudoulas and A. K. Hatzopoulos
Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease
Dis. Model. Mech.,
July 1, 2009;
2(7-8):
344 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rupp, M. Koyanagi, M. Iwasaki, J. Bauer, S. von Gerlach, D. Schranz, A. M. Zeiher, and S. Dimmeler
Characterization of long-term endogenous cardiac repair in children after heart transplantation
Eur. Heart J.,
August 1, 2008;
29(15):
1867 - 1872.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Povsic and P. J. Goldschmidt-Clermont
Review: Endothelial progenitor cells: markers of vascular reparative capacity
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
199 - 213.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Atoui, J.-F. Asenjo, M. Duong, G. Chen, R. C.-J. Chiu, and D. Shum-Tim
Marrow Stromal Cells as Universal Donor Cells for Myocardial Regenerative Therapy: Their Unique Immune Tolerance
Ann. Thorac. Surg.,
February 1, 2008;
85(2):
571 - 579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Muller, A. Kazakov, A. Semenov, M. Bohm, and U. Laufs
Pressure-induced cardiac overload induces upregulation of endothelial and myocardial progenitor cells
Cardiovasc Res,
January 1, 2008;
77(1):
151 - 159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Saha, R Zbinden, S R Redwood, and M S Marber
Stem cells to repair the broken heart: much ado about nothing?
Heart,
December 1, 2006;
92(12):
1717 - 1719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Pfeiffer, P. Muller, A. Kazakov, I. Kindermann, and M. Bohm
Time-Dependent Cardiac Chimerism in Gender-Mismatched Heart Transplantation Patients
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
843 - 845.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-M. Guo, Y.-S. Zhao, H.-X. Chang, C.-Y. Wang, L.-L. E, X.-A. Zhang, C.-M. Duan, L.-Z. Dong, H. Jiang, J. Li, et al.
Creation of Engineered Cardiac Tissue In Vitro From Mouse Embryonic Stem Cells
Circulation,
May 9, 2006;
113(18):
2229 - 2237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Anversa, A. Leri, and J. Kajstura
Cardiac Regeneration
J. Am. Coll. Cardiol.,
May 2, 2006;
47(9):
1769 - 1776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kanellakis, N. J. Slater, X.-J. Du, A. Bobik, and D. J. Curtis
Granulocyte colony-stimulating factor and stem cell factor improve endogenous repair after myocardial infarction
Cardiovasc Res,
April 1, 2006;
70(1):
117 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-H. Zimmermann and T. Eschenhagen
Questioning the relevance of circulating cardiac progenitor cells in cardiac regeneration
Cardiovasc Res,
December 1, 2005;
68(3):
344 - 346.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ausoni, T. Zaglia, A. Dedja, R. Di Lisi, M. Seveso, E. Ancona, G. Thiene, E. Cozzi, and S. Schiaffino
Host-derived circulating cells do not significantly contribute to cardiac regeneration in heterotopic rat heart transplants
Cardiovasc Res,
December 1, 2005;
68(3):
394 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Leri, J. Kajstura, and P. Anversa
Cardiac Stem Cells and Mechanisms of Myocardial Regeneration
Physiol Rev,
October 1, 2005;
85(4):
1373 - 1416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Yamani, N. B. Ratliff, D. J. Cook, E. M. Tuzcu, Y. Yu, R. Hobbs, G. Rincon, C. Bott-Silverman, J. B. Young, N. Smedira, et al.
Peritransplant Ischemic Injury Is Associated With Up-Regulation of Stromal Cell-Derived Factor-1
J. Am. Coll. Cardiol.,
September 20, 2005;
46(6):
1029 - 1035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Kraitchman, M. Tatsumi, W. D. Gilson, T. Ishimori, D. Kedziorek, P. Walczak, W. P. Segars, H. H. Chen, D. Fritzges, I. Izbudak, et al.
Dynamic Imaging of Allogeneic Mesenchymal Stem Cells Trafficking to Myocardial Infarction
Circulation,
September 6, 2005;
112(10):
1451 - 1461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L Weissberg and A. Qasim
Stem cell therapy for myocardial repair
Heart,
May 1, 2005;
91(5):
696 - 702.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Hunninghake
Cardiovascular Disease in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
April 1, 2005;
2(1):
44 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Friedrich and M. Bohm
Human umbilical cord blood cells and myocardial infarction: Novel ways to treat an old problem
Cardiovasc Res,
April 1, 2005;
66(1):
4 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Schachinger and A. M. Zeiher
Stem Cells and Cardiovascular and Renal Disease: Today and Tomorrow
J. Am. Soc. Nephrol.,
March 1, 2005;
16(3_suppl_1):
S2 - S6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Deten, H. C. Volz, S. Clamors, S. Leiblein, W. Briest, G. Marx, and H.-G. Zimmer
Hematopoietic stem cells do not repair the infarcted mouse heart
Cardiovasc Res,
January 1, 2005;
65(1):
52 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Berry, T. J. Pirolli, V. Jayasankar, K. J. Morine, M. A. Moise, O. Fisher, T. J. Gardner, P. H. Patterson, and Y. J. Woo
Targeted overexpression of leukemia inhibitory factor to preserve myocardium in a rat model of postinfarction heart failure
J. Thorac. Cardiovasc. Surg.,
December 1, 2004;
128(6):
866 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nagaya, T. Fujii, T. Iwase, H. Ohgushi, T. Itoh, M. Uematsu, M. Yamagishi, H. Mori, K. Kangawa, and S. Kitamura
Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis
Am J Physiol Heart Circ Physiol,
December 1, 2004;
287(6):
H2670 - H2676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Fernandez-Aviles, J. A. San Roman, J. Garcia-Frade, M. E. Fernandez, M. J. Penarrubia, L. de la Fuente, M. Gomez-Bueno, A. Cantalapiedra, J. Fernandez, O. Gutierrez, et al.
Experimental and Clinical Regenerative Capability of Human Bone Marrow Cells After Myocardial Infarction
Circ. Res.,
October 1, 2004;
95(7):
742 - 748.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Flugelman and B. S. Lewis
The promise of myocardial repair - towards a better understanding
Eur. Heart J.,
September 1, 2004;
25(17):
1483 - 1485.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Anversa, M. A. Sussman, and R. Bolli
Molecular Genetic Advances in Cardiovascular Medicine: Focus on the Myocyte
Circulation,
June 15, 2004;
109(23):
2832 - 2838.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Melo, A. S. Pachori, D. Kong, M. Gnecchi, K. Wang, R. E. Pratt, and V. J. Dzau
Molecular and Cell-Based Therapies for Protection, Rescue, and Repair of Ischemic Myocardium: Reasons for Cautious Optimism
Circulation,
May 25, 2004;
109(20):
2386 - 2393.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hocht-Zeisberg, H. Kahnert, K. Guan, G. Wulf, B. Hemmerlein, T. Schlott, G. Tenderich, R. Korfer, U. Raute-Kreinsen, and G. Hasenfuss
Cellular repopulation of myocardial infarction in patients with sex-mismatched heart transplantation
Eur. Heart J.,
May 1, 2004;
25(9):
749 - 758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. MELO, A. S. PACHORI, D. KONG, M. GNECCHI, K. WANG, R. E. PRATT, and V. J. DZAU
Gene and cell-based therapies for heart disease
FASEB J,
April 1, 2004;
18(6):
648 - 663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. CHEN, Q. KE, Y. YANG, J. S. RANA, J. TANG, J. P. MORGAN, and Y.-F. XIAO
Cardiomyocytes overexpressing TNF-{alpha} attract migration of embryonic stem cells via activation of p38 and c-Jun amino-terminal kinase
FASEB J,
December 1, 2003;
17(15):
2231 - 2239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Barbash, P. Chouraqui, J. Baron, M. S. Feinberg, S. Etzion, A. Tessone, L. Miller, E. Guetta, D. Zipori, L. H. Kedes, et al.
Systemic Delivery of Bone Marrow-Derived Mesenchymal Stem Cells to the Infarcted Myocardium: Feasibility, Cell Migration, and Body Distribution
Circulation,
August 19, 2003;
108(7):
863 - 868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Korbling and Z. Estrov
Adult Stem Cells for Tissue Repair -- A New Therapeutic Concept?
N. Engl. J. Med.,
August 7, 2003;
349(6):
570 - 582.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Cogle, S. M. Guthrie, R. C. Sanders, W. L. Allen, E. W. Scott, and B. E. Petersen
An Overview of Stem Cell Research and Regulatory Issues
Mayo Clin. Proc.,
August 1, 2003;
78(8):
993 - 1003.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. D. Dowell, M. Rubart, K. B.S. Pasumarthi, M. H. Soonpaa, and L. J. Field
Myocyte and myogenic stem cell transplantation in the heart
Cardiovasc Res,
May 1, 2003;
58(2):
336 - 350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Reffelmann and R. A. Kloner
Cellular cardiomyoplasty--cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure?
Cardiovasc Res,
May 1, 2003;
58(2):
358 - 368.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Luttun and P. Carmeliet
De novo vasculogenesis in the heart
Cardiovasc Res,
May 1, 2003;
58(2):
378 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Muller, M. Bohm, D. A. Taylor, R. Hruban, E. R. Rodriguez, and P. Goldschmidt-Clermont
Chimerism as a Mechanism of Self-Repair * Response
Circulation,
March 11, 2003;
107
(9):
e69 - e69.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Deb, S. Wang, K. A. Skelding, D. Miller, D. Simper, and N. M. Caplice
Bone Marrow-Derived Cardiomyocytes Are Present in Adult Human Heart: A Study of Gender-Mismatched Bone Marrow Transplantation Patients
Circulation,
March 11, 2003;
107(9):
1247 - 1249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Nadal-Ginard, J. Kajstura, A. Leri, and P. Anversa
Myocyte Death, Growth, and Regeneration in Cardiac Hypertrophy and Failure
Circ. Res.,
February 7, 2003;
92(2):
139 - 150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Q. Daley, M. A. Goodell, and E. Y. Snyder
Realistic Prospects for Stem Cell Therapeutics
Hematology,
January 1, 2003;
2003(1):
398 - 418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Sauer, J. Hescheler, and M. Wartenberg
Cardiac differentiation of mesenchymal stem cells in sex mis-matched transplanted hearts: self-repair or just a visit?
Cardiovasc Res,
December 1, 2002;
56(3):
357 - 358.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.E. MURRY, M.L. WHITNEY, M.A. LAFLAMME, H. REINECKE, and L.J. FIELD
Cellular Therapies for Myocardial Infarct Repair
Cold Spring Harb Symp Quant Biol,
January 1, 2002;
67(0):
519 - 526.
[Abstract]
[PDF]
|
|
|
Top
Abstract
Introduction
